• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2005 Fiscal Year Final Research Report Summary

The development of a novel genetherapy for pelitoneal dissemination of ovarian cancer using HSV-1 and its amplicon system.

Research Project

Project/Area Number 15591791
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionNagoya University (2005)
Aichi Cancer Center Research Institute (2003-2004)

Principal Investigator

NAWA Akihiro  Nagoya University, Graduate School of Medicine, Associate Professor, 大学院・医学系研究科, 助教授 (90242859)

Co-Investigator(Kenkyū-buntansha) NISHIYAMA Yukihiro  Nagoya University, Graduated School of Medicine, Professor, 大学院・医学系研究科, 教授 (60115615)
TSURUMI Tatsuya  Aichi Cancer Center, Research Institute, Director, 研究所, 部長 (90172072)
Project Period (FY) 2003 – 2005
KeywordsHSV amplicon / rabbit-carboxyl esterase / taxol prodrug / MDR expressing cells / clear cell carcinoma cells of the ovary
Research Abstract

We demonstrated that oncolytic HSV 1 mutants very effectively treated peritoneally disseminated ovarian cancer in a mouse model.
To aid in the development of paclitaxel (TAX) prodrugs for gene-directed enzyme prodrug therapy (GDEPT), we examined the cytotoxicity of TAX-2'-Et in a human clear cell carcinoma of the ovary cell line (KOC-7c), which had been transfected with a rabbit carboxylesterase (Ra-CES) cDNA. Transfection of Ra-CES into MDR(P-gp)-expressing KOC-7c cells conferred a high level of TAX-2'-Et cytotoxicity via prodrug activation. The intracellular levels of TAX for a specific exposure time were significantly increased in cells treated with TAX-2'-Et in Ra-CES-positive KOC-7c cells over the levels seen in TAX-treated cells. In conclusion, TAX-2'-Et can circumvent P-gp-associated cellular efflux of TAX. TAX-2'-Et is converted into TAX by the Ra-CES, supporting its potential use as a theoretical GDEPT strategy for TAX therapy. The TAX-2'-Et prodrug efficiently increased the amount of intracellular TAX, which mediates tumor cell death. Moreover, we have developed a virus cocktail containing HSV1 HF-10 and HSV1 amplicon expressing Ra-CES in the ratio of 1:5. We are examining an efficacy of the combination of the cocktail and TAX-2'-Et to the KOC-7c cells, which reveal TAX-resistance markedly.

  • Research Products

    (2 results)

All 2003

All Journal Article (2 results)

  • [Journal Article] Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.2003

    • Author(s)
      Akihiro Nawa
    • Journal Title

      Gynecol Oncol 91

      Pages: 81-8

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type 1 mutant in a mouse model.2003

    • Author(s)
      Akihiro Nawa
    • Journal Title

      Gynecol Oncol 91

      Pages: 81-88

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2007-12-13  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi